ArticleEndocrinology, diabetes & metabolism2026
Evaluation of High-Density Lipoprotein Capacity to Acquire Free Cholesterol From Triglyceride-Rich Lipoproteins During Reverse Remnant-Cholesterol Transport in Familial Hypercholesterolemia.
Article in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionHigh-density lipoprotein (HDL) serves as a key protective factor against elevated low-density lipoprotein cholesterol (LDL-C) levels in patients with familial hypercholesterolemia (FH). This study aimed to assess whether HDL's ability to acquire free cholesterol (FC) from triglyceride-rich lipoproteins (TGRLs) during lipolysis, as a part of reverse remnant-cholesterol transport (RRT) pathway, is impaired in FH patients.
methodsThis case-control study included 16 homozygous (HOFH) and 18 heterozygous (HEFH) patients with FH, along with 20 healthy controls. The free cholesterol transfer assay measured the ability of HDL (as apoB-depleted serum) to uptake fluorescently labelled free cholesterol (TopF) from TGRLs during lipoprotein lipase (LPL)-mediated lipolysis.
resultsNo significant difference was observed among the groups in the overall capacity of HDL to acquire FC from TGRLs during LPL-mediated lipolysis. When normalizing for LDL-C and non-HDL-C levels, significantly lower TopF transfer/LDL-C and TopF transfer/non-HDL-C ratios were observed in HOFH patients in comparison with HEFH and healthy subjects. Lower TopF transfer/LDL-C (OR: 0.605, 95% CI: 0.428-0.857; p < 0.01) and TopF transfer/non-HDL-C (OR: 0.539, 95% CI: 0.339-0.859; p < 0.01) ratios were independently associated with HOFH, while, after adjusting for age only the former association remained significant (OR: 0.646, 95% CI: 0.430-0.971).
conclusionAlthough HDL's direct capacity to acquire free cholesterol from TGRLs did not differ significantly between the groups, the reduced TopF transfer/LDL-C and TopF transfer non-HDL-C ratios in FH patients is consistent with impaired HDL function. These ratios may serve as a potential biomarker for identifying high-risk FH phenotypes, warranting validation in larger, prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.